Previous article
Pigmented Lesion on the Hard Palate
Mar 2025
Next article
In Older Adults With Type 2 Diabetes, GLP-1 Receptor Agonists Decrease Major Adverse Cardiovascular Events; SGLT-2 Inhibitors Prevent Heart Failure Hospitalizations
Point-of-Care Guides

Predicting the Risk of Esophageal Adenocarcinoma in People With Barrett Esophagus

Mark H. Ebell, MD, MS

American Family Physician. 2025;111(3):279-280.

Author disclosure: No relevant financial relationships.

This clinical content conforms to AAFP criteria for CME.

MARK H. EBELL MD, MS, Michigan State University, East Lansing

Address correspondence to Mark H. Ebell, MD, MS, at Ebell.mark@gmail.com.

Author disclosure: No relevant financial relationships.

  1. 1.Runge TM, Abrams JA, Shaheen NJ. Epidemiology of Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am. 2015;44(2):203-231.
  2. 2.Kubo A, Levin TR, Block G, et al. Alcohol types and sociodemographic characteristics as risk factors for Barrett's esophagus. Gastroenterology. 2009;136(3):806-815.
  3. 3.Cook MB, Thrift AP. Epidemiology of Barrett's esophagus and esophageal adenocarcinoma: implications for screening and surveillance. Gastrointest Endosc Clin N Am. 2021;31(1):1-26.
  4. 4.Weusten BLAM, Bisschops R, Dinis-Ribeiro M, et al. Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2023;55(12):1124-1146.
  5. 5.Shaheen NJ, Falk GW, Iyer PG, et al. Diagnosis and management of Barrett's esophagus: an updated ACG guideline. Am J Gastroenterol. 2022;117(4):559-587.
  6. 6.Thrift AP, Kendall BJ, Pandeya N, et al. A model to determine absolute risk for esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2013;11(2):138-44.e2.
  7. 7.Brown CS, Lapin B, Goldstein JL, et al. Predicting progression in Barrett's esophagus: development and validation of the Barrett's Esophagus Assessment of Risk score (BEAR Score). Ann Surg. 2018;267(4):716-720.
  8. 8.Parasa S, Vennalaganti S, Gaddam S, et al. Development and validation of a model to determine risk of progression of Barrett's esophagus to neoplasia. Gastroenterology. 2018;154(5):1282-1289.e2.

This guide is one in a series that offers evidence-based tools to assist family physicians in improving their decision-making at the point of care.

This series is coordinated by Mark H. Ebell, MD, MS, deputy editor for evidence-based medicine.

A collection of Point-of-Care Guides published in AFP is available at https://www.aafp.org/afp/poc.

Previous article
Pigmented Lesion on the Hard Palate
Mar 2025
Next article
In Older Adults With Type 2 Diabetes, GLP-1 Receptor Agonists Decrease Major Adverse Cardiovascular Events; SGLT-2 Inhibitors Prevent Heart Failure Hospitalizations

Current issue

May 2026

May 2026

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.